Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

83.18 +1.63 (+2.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy
 
Via Benzinga
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer. 
Via Benzinga
Palantir, Hertz, Metsera, Uber, DraftKings: Stocks Making The Biggest Moves Today
Via Stocktwits
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
Via Stocktwits
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit
Via Stocktwits
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further
According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 
Via Stocktwits
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech. 
Via Investor's Business Daily
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera. 
Via Stocktwits
Topics Law Enforcement
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins. 
Via Stocktwits
Topics Lawsuit
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk. 
Via Benzinga
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. 
Via Benzinga
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid. 
Via Investor's Business Daily
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. 
Via Stocktwits
Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
These two leading drugmakers are fighting over a promising GLP-1 candidate. 
Via The Motley Fool
Topics Intellectual Property
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk. 
Via Investor's Business Daily
Topics Economy Lawsuit
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal. 
Via Benzinga
Topics Lawsuit
Meet the 7% Yield Dividend Stock That Could Soar in 2026
This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term. 
Via The Motley Fool
Topics Intellectual Property World Trade
Is It Time to Dump Your Shares of Pfizer?
Pfizer stock has dropped 50% over the past three years. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company. 
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.